A phase II study of post-remission therapy with pembrolizumab in older patients with acute myeloid leukemia.

Autor: Quann K; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh PA; UPMC Hillman Cancer Center. quannka@pitt.edu., Lontos K; UPMC Hillman Cancer Center., Sehgal A; UPMC Hillman Cancer Center., Raptis A; UPMC Hillman Cancer Center., Im A; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh PA; UPMC Hillman Cancer Center., Redner RL; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh PA; UPMC Hillman Cancer Center., Dorritie KA; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh PA; UPMC Hillman Cancer Center., Agha M; UPMC Hillman Cancer Center., Hou JZ; UPMC Hillman Cancer Center., Farah R; UPMC Hillman Cancer Center., Rossetti J; UPMC Hillman Cancer Center., Normolle DP; Department of Biostatistics, University of Pittsburgh School of Public Health., Whiteside TL; UPMC Hillman Cancer Center, Pittsburgh, PA; Department of Pathology, University of Pittsburgh School of Medicine., Hsu YS; Immunologic Monitoring and Cellular Products Laboratory, UPMC Hillman Caner Center., Boyiadzis M; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine.
Jazyk: angličtina
Zdroj: Haematologica [Haematologica] 2024 Aug 08. Date of Electronic Publication: 2024 Aug 08.
DOI: 10.3324/haematol.2024.285313
Abstrakt: Not available.
Databáze: MEDLINE